Indian firms produce about 60,000 generic brands across 60 therapeutic categories. India is also among the world’s leading vaccine producers. Clinical trials in India cost one-tenth of that in the US. R&D costs in India are one-eighth of that in the US. India has the highest number (119) of the USFDA-approved manufacturing plants outside the US.
Biotechnology has several constituent segments of which, bio-pharma segment accounts for the majority of the biotech industry’s revenues. Bioinformatics is another segment, which is a US$ 48.4 million (2008–09) industry in India and offers several investment opportunities.
In 2008–09, the biotech industry recorded revenues worth US$ 2.67 billion (INR 121.37 billion), registering a y-o-y growth of 18 per cent (in value) from 2007–08. The leading ten companies (in terms of revenues) accounted for 39 per cent of the total industry revenues in 2008–09. Revenues from biotech exports have been valued at US$ 1.57 billion in 2008–09, constituting 59 per cent of the total biotech industry revenues.
The biotechnology-related infrastructure has evolved from traditional clusters to specialised industrial infrastructure such as biotech or science parks. Currently, there are about 26 operational parks in the country.
MNCs such as Novo Nordisk and Novozymes feature among the leading 10 biotech companies.
There are various international collaborations with different countries in the offing, which are directed at enabling an effective transition of knowledge. To achieve this, India has partnered with Denmark, Finland, France, the UK, the US, Switzerland and the Netherlands.
Serum Institute of India and Biocon are the two leading biotech players in the industry.Sectoral Presentation (April 2010)
Click here to Download File (Size: 344.59 KB )